Correlation of genes associated with drug response to prognosis of large cell lung carcinoma.

摘要: Platinum-based chemotherapy remains the main treatment of advanced lung cancer. However, platinum resistance has become a major obstacle. Novel therapies, particularly tyrosine kinase inhibitors epidermal growth factor receptor (EGFR-TKI) and agents that target vascular endothelial (VEGF), have improved treatment. Both targeted therapy their molecular mechanisms. This study aimed to determine mutation, amplification, or expression status interrelationships (EGFR), K-Ras proto-oncogene, excision repair cross-complementation group 1 (ERCC1), VEGF genes as well correlations prognosis large cell carcinoma (LCLC) after EGFR-targeted therapy, chemotherapy, anti-VEGF therapy. EGFR mutations in 60 specimens LCLC were detected by direct DNA sequencing. EGFR, ERCC1, protein was immunohistochemistry (IHC). gene copy number fluorescence situ hybridization (FISH). One (1.7%) patient had an L858M point mutation exon 21, 3 (5.0%) mutations, 10 (19.6%) amplification (FISH positive). Positive rates proteins 38.3%, 56.7%, 70.0%, respectively. positively correlated (r = 0.390, P 0.005). The positive rate significantly higher patients with lymph node metastasis than those without (84.6% vs. 58.8%, 0.046). No significant observed among K-Ras, genes. low suggest are likely obtain little benefit from anti-EGFR therapies.